FDAsafety guidance66% confidence
FDA AP — PARICALCITOL (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA205917. Sponsor: HIKMA PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PARICALCITOL.
Supporting Context
- Therapeutic area
- Endocrinology · Vitamin D Analog
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Paricalcitol by Hikma Pharmaceuticals